Get the Stockscreener App
10.73
4.79%
-0.54
Greenwich Lifesciences Inc stock is traded at $10.73, with a volume of 154.98K.
It is down -4.79% in the last 24 hours and up +28.89% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$11.27
Open:
$11.98
24h Volume:
154.98K
Relative Volume:
1.90
Market Cap:
$148.66M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-15.33
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
+20.02%
1M Performance:
+28.89%
6M Performance:
+13.31%
1Y Performance:
-18.77%
1-Day Range:
$10.51
$11.98
1-Week Range:
$9.20
$11.98
52-Week Range:
$7.78
$14.47
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
10.73 | 156.14M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
What is Noble Financial’s Estimate for GLSI FY2025 Earnings? - Defense World
What drives Greenwich LifeSciences Inc stock price - earlytimes.in
Aug Retail: Will Greenwich LifeSciences Inc stock outperform growth indexesTreasury Yields & Expert-Curated Trade Recommendations - moha.gov.vn
Noble Financial Issues Pessimistic Outlook for GLSI Earnings - MarketBeat
(GLSI) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Greenwich LifeSciences completes enrollment in Phase III trial arm - Investing.com
Greenwich LifeSciences completes enrollment in Phase III trial arm By Investing.com - Investing.com India
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 - The Manila Times
Greenwich LifeSciences (Nasdaq: GLSI) finishes 250-patient arm, targets 88,000 eligible - Stock Titan
How Greenwich LifeSciences Inc. stock reacts to global recession fearsMarket Growth Summary & Real-Time Volume Trigger Notifications - Newser
What analysts say about Greenwich LifeSciences Inc stockShort Selling Opportunities & Identify Winning Stocks - earlytimes.in
Greenwich LifeSciences reaches 1,000 patient screening milestone By Investing.com - Investing.com Nigeria
Greenwich Lifesciences provides global update on Flamingo-01 - marketscreener.com
Greenwich LifeSciences reaches 1,000 patient screening milestone - Investing.com
Greenwich LifeSciences, Inc. Reports Milestone Achievement in FLAMINGO-01 Clinical Trial with Over 1,000 Patients Screened - Quiver Quantitative
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date - Yahoo Finance
Greenwich LifeSciences (GLSI) Stock Analysis Report | Financials & Insights - Benzinga
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $38,502.00 in Stock - MarketBeat
(GLSI) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Greenwich LifeSciences CEO Patel buys $38k in GLSI stock By Investing.com - Investing.com Canada
Is Greenwich LifeSciences Inc. stock safe for conservative investorsRate Cut & Real-Time Volume Analysis - newser.com
Why Greenwich LifeSciences Inc. stock remains on watchlistsEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Greenwich LifeSciences Inc. stock daily chart insightsQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
What recovery options are there for Greenwich LifeSciences Inc.July 2025 Summary & Expert Approved Momentum Trade Ideas - newser.com
(GLSI) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Can Greenwich LifeSciences Inc. stock surprise with earnings upside2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Greenwich LifeSciences (NASDAQ:GLSI) Releases Earnings Results, Meets Expectations - MarketBeat
How to interpret RSI for Greenwich LifeSciences Inc. stockMarket Growth Summary & Expert Curated Trade Ideas - newser.com
Key resistance and support levels for Greenwich LifeSciences Inc.Watch List & Community Verified Swing Trade Signals - newser.com
Published on: 2025-11-14 19:58:18 - newser.com
Published on: 2025-11-14 17:28:35 - newser.com
Greenwich LifeSciences, Inc. SEC 10-Q Report - TradingView
Published on: 2025-11-14 13:13:03 - newser.com
When is the best time to exit Greenwich LifeSciences Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
What candlestick patterns are forming on Greenwich LifeSciences Inc.July 2025 Setups & Verified Swing Trading Watchlists - newser.com
Several Insiders Invested In Greenwich LifeSciences Flagging Positive News - Yahoo Finance
Is Greenwich LifeSciences Inc a good long term investmentLong-Term Growth Stocks & Small Budget Capital Growth - earlytimes.in
Published on: 2025-11-13 03:10:11 - newser.com
Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $89,358.00 in Stock - MarketBeat
Greenwich LifeSciences CEO Makes Bold Stock Purchase! - TipRanks
Greenwich LifeSciences CEO and CFO Snehal Patel Acquires 10,600 Shares - TradingView
[Form 4] Greenwich LifeSciences, Inc. Insider Trading Activity - Stock Titan
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):